Morning Brief, Friday 21 August

Russian forces launched a nine-hour overnight barrage of ballistic missiles, cruise missiles and drones at Kyiv and other Ukrainian regions, killing 16 people and wounding more than 40, according to Ukrainian emergency authorities. Strikes hit apartment blocks, schools and warehouses in Kyiv, while the Russian Defence Ministry claimed it targeted military depots, logistics facilities and drone-component workshops. Ukrainian officials also reported damage in Odesa and Chernihiv, and Kyiv mayor Vitali Klitschko announced a day of mourning for Friday.

Volodymyr Zelensky said Russia had prepared the operation to maximise damage to civilian infrastructure.

The barrage pushed the war toward NATO airspace again. Poland mobilised aircraft and put ground-based air defences on alert, while Romania deployed Spanish fighters and a military helicopter after radar tracked targets near its border. Romanian officials said an uncrewed aerial vehicle entered national airspace near Galati and fell in an unpopulated area, and the defence minister said an F-16 intercepted an explosive sea drone near the Neptun Deep gas platform. Russian officials, meanwhile, reported Ukrainian drone activity toward Moscow and said air defences intercepted 28 drones in the Moscow region.

The bombardment turns air defence from a Ukrainian battlefield need into a NATO border-management problem, which is exactly where a long war becomes harder to contain.

Spanish police began clearing an improvised migrant camp at El Trampolín beach in Ceuta at 7:30am, escorting between 1,200 and 1,700 people to temporary accommodation. Sub-Saharan migrants went to Loma Margarita, while Maghreb nationals walked to military tents near the Tarajal border and Ceuta University Hospital. The operation soon stalled after roughly 500 people returned to the beach carrying blankets, which rather spoiled the impression of a solved problem.

The numbers explain the strain. Three weeks after the 30 July border rush, when 72,000 people crossed into the Spanish exclave, local officials estimate 9,000 to 10,000 migrants remain, including about 2,000 minors. Spain's Interior Ministry puts the figure closer to 5,000, while UNHCR says about 1,200 people qualify for international protection and should move faster through asylum processing. Madrid plans to transfer 500 unaccompanied female minors to mainland regions, citing unsafe conditions and reports of sexual assault.

Health Minister Mónica García defended the transfer plan as a safety measure.

The politics have turned sharp. Ceuta president Juan Jesús Vivas accused Madrid of providing too few resources, saying local officials process only 25 to 30 expulsion files a day. Opposition parties in Madrid are summoning ministers, while Andalusia said it would accept minors under legal quotas. Ceuta now shows what happens when a border crisis outpaces both paperwork and political patience.

America's gross federal debt passed $40 trillion for the first time after a Treasury bond issuance lifted the total to $40.047 trillion. The milestone arrived earlier than the Congressional Budget Office expected in 2023, and debt has risen by $1 trillion in less than five months. Borrowing has doubled since January 2017, while annual deficits run at roughly 6% to 7% of GDP and total debt stands near 125% of output.

The Treasury tried to calm the market by doubling long-bond buybacks to $4 billion per operation from September, targeting 10-year to 30-year debt. The announcement briefly helped fixed income, but yields climbed again on Thursday, with the 10-year Treasury at 4.69% and the 30-year at 5.23%. Treasury Secretary Scott Bessent said repurchases could grow if conditions require it, but the move also revealed a government leaning harder against a market that is demanding more compensation for duration risk.

Bessent played down the symbolism of the number while defending growth as the escape route.

That argument now competes with expensive wars, tariff refunds, entitlement spending and high refinancing costs. Long bonds are no longer a quiet plumbing issue for specialists; they transmit fiscal doubts directly into mortgages, corporate borrowing and the dollar. The $40 trillion line may be arbitrary, but the interest bill is not.

A court in Shenzhen sentenced Evergrande founder Hui Ka Yan to life in prison after convicting him of eight financial crimes, and ordered the confiscation of his personal assets. Judges imposed 15.82 billion yuan in corporate fines across Evergrande entities and sentenced 56 people linked to the company's collapse, including executives, fundraising agents and Hui's two sons. The court said the group disrupted China's property market and caused severe damage across domestic banking and investment sectors.

Evergrande's rise and fall tracked the whole Chinese property cycle with uncomfortable neatness. Hui founded the company in Guangzhou in 1996, listed it in Hong Kong in 2009, and used debt to turn it into China's top-selling developer, with annual sales reaching $100 billion in 2020. Regulators later found that Evergrande inflated revenues by $78 billion, while investigations said pre-sale funds from homebuyers went into land purchases rather than construction, leaving hundreds of residential projects unfinished.

Hui had once described poverty as the origin story behind his empire.

The collapse accelerated after Beijing tightened leverage rules in 2020. Evergrande defaulted on most of its $300 billion in liabilities in 2021, suspended share trading in 2022, reported combined net losses of 581.9 billion yuan for 2021 and 2022, and was later delisted and ordered into liquidation. Hui's sentence is not just punishment for fraud; it warns developers, creditors and local officials that Beijing wants the speculative property model remembered as a cautionary tale, not a rescue request.

Moderna and Merck announced that their personalised mRNA cancer vaccine, intismeran autogene, met the primary endpoint in a Phase 3 melanoma trial involving 1,137 patients. The study tested the vaccine alongside Keytruda after surgical tumour removal in stage 2B to stage 4 melanoma, and the companies said the combination improved recurrence-free survival and reduced metastasis compared with Keytruda alone. They plan to present detailed data at a medical meeting before seeking regulatory approval.

The treatment works by sequencing each patient's tumour after surgery, identifying up to 34 neoantigens and using mRNA to train the immune system to spot mutated cancer cells. Production takes about six weeks, which makes the medicine both scientifically elegant and operationally demanding. The companies said the vaccine added no new severe side effects beyond known Keytruda toxicities, and earlier Phase 2 data showed a 44% reduction in recurrence or death versus Keytruda alone.

Stéphane Bancel framed the result as a validation of individualised mRNA medicine.

Markets reacted as if the pandemic-era mRNA promise had found a second act: Moderna shares jumped 177%, Merck rose 13% and BioNTech gained nearly 22%. The science still needs full data, regulators and manufacturing discipline, but a bespoke cancer shot has moved from intriguing theory to commercial race.